Treatment of Rheumatoid Arthritis(pain and swelling in joints) with Unani medicines Majoon-e-Azaraqi and Roghan-e-Surkh

An Open label, Clinical Validation study to Evaluate the Efficacy and Safety of Unani Pharmacopieal Formulations Majoon-e-Azaraqi and Roghan-e-Surkh in Waja-ul-Mafasil (Rheumatoid Arthritis)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/05/033636

Enrollment

110

Registered

2021-05-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: Majoon-e-Azaraqi and Roghan-e-Surkh: Majoon Azraqi: 3 gms orally twice daily with water, Roghan-e-Surkh: 2ml oil locally. duration of treatment is twelve weeks Control Intervention1: N

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of either sex in the age group 18-65 years. 2. Subjectshaving total score of >=6/10 in ACR-EULAR criteria for diagnosis of Wajaâ??al-Mafasil (Rheumatoid Arthritis)

Exclusion criteria

Exclusion criteria: 1. Rheumatoid arthritis with extra-articular manifestations, joint deformities, and advanced radiological lesions (e.g. joint subluxation and collapse). 2. Obese subjects (BMI >=30) 3. History or clinical evidence of any systemic inflammatory condition other than RA such as, juvenile chronic arthritis, spondyloarthropathy, IBD, psoriatic arthritis, active vasculitis, or gout that may interfere with evaluation. 4. History or clinical evidence of any serious systemic illness, DM, TB, disseminated/ complicated herpes zoster (e.g., multi-dermatomal involvement, ophthalmic zoster, CNS involvement, or post-herpetic neuralgia), HIV infection or any other serious and/ or unstable illness that, in the opinion of the investigator, could constitute a risk when taking study drug or could interfere with the interpretation of data. 5. Screening laboratory test values, including SGOT, SGPT, ALP, S. creatinine, B. urea, and S. uric acid outside the reference range (raised >3 times the ULN) that, in the opinion of the investigator, could pose an unacceptable risk to the participant. 6. History of hypersensitivity to study drug or any of its ingredients. 7. Pregnant and lactating women 8. H/o Addiction (alcohol, drugs)

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms of Waja-ul-Mafasil (Rheumatoid Arthritis)Timepoint: 2 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: at baseline and 12 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026